Pfizer stock has rebounded over the past year after a weak few years, yet the broader valuation checks and current market multiples still suggest the shares are not a clear bargain at today’s price.

• The stock has fallen 27.4% over the past 5 years, which means long term holders have yet to fully recover despite the recent improvement.
• Recent product news and new trial results can support confidence in future cash flows, while concerns about patent expirations and integration of recent acquisitions may weigh on how much investors are willing to pay for that growth.
• Pfizer scores 3 out of 6 on our valuation checks, which points to a mixed picture rather than clearly cheap or clearly expensive on a broad set of fundamentals, and you can see the breakdown at 3.

The issue now is whether Pfizer’s current share price fairly reflects those mixed signals or if the recent rebound has already used up most of the potential upside.

Is Pfizer Getting Expensive on Earnings?

The P/E ratio is one of the sharper tools for a mature, profit-generating group like Pfizer because it links what you pay today to the earnings already in place.

Pfizer trades on a P/E of 33.9x, which is higher than the pharmaceuticals industry average of 15.6x and below the stated peer average of 50.7x. A tailored fair P/E for Pfizer, which blends its margins, risk profile, size and sector backdrop, is estimated at 23.2x. That is a clear gap to the current multiple and points to investors paying a premium for each dollar of earnings compared with what this framework suggests as reasonable.

Despite the recent Q2 2026 earnings beat and higher revenue guidance lifting confidence, the current P/E still sits well above the fair ratio implied by these fundamentals.

On the P/E multiple, Pfizer stock currently screens as overvalued relative to this fair value benchmark.

The Pfizer Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up from that valuation puzzle around Pfizer and spell out which paths for the company’s future earnings, margins and growth would make its current share price look high or low. Each narrative ties its view of Pfizer’s potential value to a clear stance on how growth, profitability and risks might evolve, which gives you something concrete to revisit as new information comes through on the Community page.

One of the top community narratives on Pfizer: 12% undervalued

"Sustained shift of the portfolio toward high-value biologics, vaccines, and personalized therapies enables pricing power and supports premium net margins."

Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!

The Bottom Line

Pfizer screens as overvalued on current earnings multiples, so the recent rebound leaves less room for error if sentiment cools. With the broader valuation checks coming through as mixed, the stock does not stand out as a clear bargain or a clear bubble on fundamentals alone. The key question for investors now is whether Pfizer can deliver the earnings and margin progress that keeps justifying a richer P/E than the wider pharmaceuticals group.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.